Pieris Pharmaceuticals Inc (PIRS): יחס מחיר למכירות

Pieris Pharmaceuticals (PIRS) aims for the global implementation of Anticalin protein technologies to combat cancer and lung diseases, while the P/S ratio history is available for analysis on GURU.Markets, where the 821.20 level serves as a critical benchmark. The current restructuring following the dissolution of major alliances requires strict regulatory oversight, and development relies on attracting leading biologists through competitive salaries.
פילוחים אנליטיים של חברת Pieris (PIRS)

Evaluating market value relative to generated income is critical for selecting assets with a high margin of safety. This price-to-sales ratio correlates the market capitalization of Pieris Pharmaceuticals (PIRS) with licensing revenue from anti-calin proteins and royalties from AstraZeneca and Servier, allowing investors to determine the premium paid for innovative drug potential by analyzing the historical trend of this metric.